AI is Transforming Pharmaceutical Packaging: Six Trends Shaping the Future
Every prescription medicine box tells a story of precision. Behind every carton and patient information leaflet (PIL) lies a highly regulated process involving multilingual content, artwork management, regulatory compliance and an expectation of near-zero errors.
Even a small artwork error – an omitted warning, an incorrect dosage, an unreadable barcode or a misplaced graphic – can delay product launches, trigger costly recalls or attract regulatory scrutiny.
For decades, pharmaceutical companies have relied on skilled artwork and quality specialists to identify these issues manually. Today, automation and Artificial Intelligence (AI) are reshaping that process, augmenting expert judgement rather than replacing it.
Across the industry, six key trends are driving this transformation:
1. Digital Product Information is Moving into the Mainstream
Printed patient information leaflets remain a regulatory requirement in many markets, but the industry is steadily exploring electronic product information (ePI) and digital patient information.
Regulatory initiatives and pilot programmes – including work led by organisations such as the European Medicines Agency (EMA), the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and India’s Central Drugs Standard Control Organisation (CDSCO) – are evaluating how digital information can complement traditional packaging where regulations permit.
QR codes and digital platforms provide patients with multilingual, up-to-date product information while giving manufacturers greater flexibility to update approved information more efficiently and reduce paper usage where appropriate.
2. Structured Content is Becoming the Single Source of Truth
The industry is moving away from manually copying approved text between Word documents and artwork files towards structured content management based on standards such as Structured Product Labeling (SPL) and Identification of Medicinal Products (IDMP).
Rather than maintaining multiple independent copies of the same information, approved content is created once and reused consistently across cartons, leaflets, electronic labelling and regulatory submissions. This improves consistency, reduces duplication and lowers the risk of transcription errors. Structured content also provides the foundation for the next major development: intelligent quality assurance powered by AI.
3. AI is Adding Context to Traditional Validation
Traditional artwork comparison software follows predefined rules. If two files differ—even by a single pixel – it raises an alert, regardless of whether the change is meaningful. The next generation of quality assurance combines these proven rule-based systems with multimodal AI capable of interpreting text, images, barcodes and Braille together. Rather than replacing existing validation tools, AI provides an additional layer of quality assurance by helping identify contextual inconsistencies, semantic differences and layout issues that rule-based systems may not detect on their own. Once quality information becomes structured and machine-readable, AI can move beyond simple comparison to supporting more intelligent regulatory review.
4. Generative AI is Becoming a Regulatory Assistant
Large Language Models (LLMs) are beginning to support regulatory and artwork teams by assisting with first drafts of regulatory summaries, translation support, plain-language adaptations and internal documentation. Any AI-generated content must remain subject to expert human review, approval and documented quality processes before use.
Used appropriately, AI can significantly reduce administrative effort while allowing regulatory specialists to focus on higher-value scientific, regulatory and compliance decisions.
5. Collaborative Digital Platforms are Becoming the Operating Model
Pharmaceutical organisations are increasingly adopting cloud-based collaboration platforms such as Esko Cloud, Veeva Vault and Adobe Creative Cloud to streamline artwork management across globally distributed teams. These platforms enable designers, regulatory specialists and quality reviewers to collaborate securely while maintaining version control, comprehensive audit trails and controlled approval workflows.
As artwork development becomes increasingly digital, seamless collaboration is becoming as important as technical capability.
6. Data is Becoming a Strategic Asset
Every artwork project generates valuable operational and quality data. Increasingly, pharmaceutical companies are using analytics to identify recurring error patterns, monitor process performance and drive continuous improvement across artwork workflows. Rather than simply correcting errors after they occur, organisations are beginning to predict where issues are most likely to arise – creating a foundation for predictive quality, operational analytics and future AI-assisted decision support.
Taken together, these trends represent far more than incremental improvements. They signal a fundamental shift in how pharmaceutical packaging will be developed, reviewed and governed over the coming decade.
The organisations that succeed will not simply adopt AI. They will combine intelligent technology with validated processes, strong governance and experienced specialists capable of making informed regulatory decisions.
In our next article, we’ll explore how Vakils is translating these industry trends into a practical roadmap for intelligent pharmaceutical premedia.
Email us at info@vakilspremedia.com for more details on our AI-backed artwork labelling service offerings.
